Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma

Table 3 Multivariate survival analysis in overall osteosarcoma patients

Characteristics	OS		RFS
	HR (95% CI)	P	HR (95% CI)	P
Tumor size, > 8 cm (vs. ≤ 8 cm)	3.795 (1.205–11.953)	0.023	3.680 (1.249–10.842)	0.018
Distant metastasis, presence (vs. absence)	6.200 (1.603–23.984)	0.008	3.450 (0.997–11.934)	0.050
SIRT6, positive (vs. negative)	6.797 (2.129–21.702)	0.001	6.516 (2.234–19.001)	< 0.001

OS overall survival; RFS relapse-free survival; HR hazard ratio; 95% CI 95% confidence interval. The variables included in multivariate analysis were age, tumor size, stage, lymph node metastasis, distant metastasis, histologic grade, and SIRT6 expression

ISSN: 1756-9966